重组戊肝疫苗在代偿期乙肝肝硬化患者中的安全性与免疫原性
本研究在深圳纳入162名成人,分为未治疗慢性乙肝组、慢性乙肝治疗组、乙肝肝硬化组和对照组,接种重组戊肝疫苗Hecolin。结果显示代偿期乙肝肝硬化患者接种后安全,未出现与疫苗相关的严重不良事件,且免疫原性良好,支持在该高危人群中用于预防戊肝重叠感染。
要点
- 代偿期乙肝肝硬化患者接种Hecolin后7天局部不良事件发生率为13.95%,全身不良事件发生率为6.98%。
- 未发现与疫苗接种存在因果关系的严重不良事件。
- 肝硬化组接种者全部血清学转换(95%CI 88.1-100%),末剂后1个月82.8%(24/29)抗HEV IgG>1.0 WU/mL。
核心结论
- 本研究提示Hecolin在代偿期乙肝肝硬化患者中安全且具有免疫原性,支持其用于预防该高危人群的HEV重叠感染。
研究设计与样本
- 本研究于2019年11月至2022年6月在中国深圳市开展,纳入162名成人参与者,按疾病状态分为未治疗慢性乙肝组50例、慢性乙肝治疗组50例、乙肝肝硬化组43例和对照组19例。
- 安全性评估包括不良事件和肝功能检查,并在接种前、第一剂后1个月和第三剂后1个月采集血清样本检测抗HEV IgG抗体。
主要发现
- 157名(96.9%)参与者完成了三剂疫苗接种。
- 肝硬化组、治疗组、未治疗组和对照组的7天局部不良事件发生率分别为13.95%、24.0%、12.0%和5.26%,全身不良事件发生率分别为6.98%、12.0%、4.0%和0%。
- 未发现与疫苗接种存在因果关系的严重不良事件。
- 在免疫原性符合方案集中,肝硬化组所有接种者均实现血清学转换(95%CI 88.1-100%),末剂后1个月(中位38天,四分位距31-44)82.8%(24/29)抗HEV IgG水平高于1.0 WU/mL。
关键数值与推荐
- 肝硬化组7天局部不良事件发生率为13.95%,全身不良事件发生率为6.98%。
- 肝硬化组血清学转换率95%CI为88.1-100%,末剂后1个月抗HEV IgG>1.0 WU/mL者为82.8%(24/29)。
临床怎么用
- 原文结论提示Hecolin在代偿期乙肝肝硬化患者中安全且具有免疫原性,支持其用于预防该高危人群的HEV重叠感染。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Hepatitis E virus (HEV) is a global health concern that causes acute hepatitis with severe consequences, particularly in patients with chronic liver disease. Despite the availability of a recombinant hepatitis E vaccine (Hecolin), its safety and immunogenicity in patients with pre-existing liver cirrhosis remain uncertain. This study aimed to assess the safety and immunogenicity of Hecolin in individuals with compensated liver cirrhosis who have chronic hepatitis B (CHB). METHODS: This study was conducted in Shenzhen City, China, from November 2019 to June 2022. The adult participants were stratified into untreated CHB, CHB treatment, CHB cirrhosis, and control groups based on their disease status. Safety assessment included adverse events and liver function tests. Serological samples were collected before vaccination and 1 month after both the first and third doses of vaccination to assess anti-HEV IgG antibodies. RESULTS: A total of 162 eligible participants, including 43 with CHB cirrhosis, 50 with treated CHB, 50 with untreated CHB, and 19 controls were included in the study. A total of 157 (96.9%) participants received three doses of the vaccine. Safety analysis revealed 7-day local adverse events in 13.95.0%, 24.0%, 12.0%, and 5.26% and systemic adverse events in 6.98%, 12.0%, 4.0%, and 0% across the cirrhosis, treated, untreated, and control groups, respectively. No serious adverse events were deemed to be causally related to vaccination. In the per-protocol set for immunogenicity, all vaccinated participants with cirrhosis (95% CI, 88.1-100%) were seroconverted, and 82.8% (24/29) had anti-HEV IgG levels higher than 1.0 WU/mL at 1 month after the final dose (median, 38 days; interquartile range, 31-44). DISCUSSION: This study suggests that Hecolin is safe and immunogenic in patients with CHB with compensated liver cirrhosis, supporting its use in preventing HEV superinfection in this high-risk population.
引用
- Liao X, Li D, Su Y, et al. Safety and immunogenicity of hepatitis E vaccine in compensated liver cirrhosis with chronic hepatitis B. Clin Microbiol Infect. 2025. PMID: 40024530. doi:10.1016/j.cmi.2025.02.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。